TABLE 4.
Clinical and laboratory differences between COVID-19 and sHLH patients
| Finding | Value for disease (reference[s])a |
|||
|---|---|---|---|---|
| S-COVID-19 (202) | IAHS (203–205) | MAS (202) | MHLH (206) | |
| Fever | +++ | +++ | +++ | +++ |
| Hepatomegaly | + | +++ | ++ | +++ |
| Splenomegaly | − | +++ | ++ | +++ |
| Hemophagocytosis | +/− | +++ | +++ | +++ |
| Lymphopenia | ++ | +++ | + | +++ |
| Anemia | + | +++ | + | +++ |
| Low NK activity | + | + | + | NR |
| Elevated liver enzymes | ++ | ++ | ++ | +++ |
| Hypercytokinemia | +++ | +++ | +++ | NR |
| Hyperferritinemia | ++ | +++ | +++ | NR |
| Elevated sCD25 | + | NR | + | NR |
| Hypertriglyceridemia | +/− | +++ | ++ | NR |
| Hypofibrinogenemia | +/− | +++ | ++ | +++ |
| Coagulopathy | ++ | +++ | ++ | +++ |
| Multiorgan failure | +++ | +++ | + | +++ |
| ARDS | +++ | +++ | + | +++ |
a
Abbreviations: S-COVID-19, severe COVID-19; IAHS, infection-associated hemophagocytic syndrome; MAS, macrophage activation syndrome; MHLH, malignancy-associated HLH; NR, none reported; −, negative; +/−, not essential; +, slight; ++ moderate; +++, severe.